Abstract
After intravenous bolus injections of 0.5, 1, and 2 g of cefotiam to three healthy volunteers, the mean (+/- standard deviation) total plasma clearances measured for each dose were, respectively, 26.8 +/- 2.7, 22.8 +/- 0.8, and 17.8 +/- 0.9 liters/h; the terminal elimination half-lives were 54.0 +/- 0.1, 68 +/- 15, and 98 +/- 36 min; and the renal clearances were 16.0 +/- 2.9, 13.3 +/- 1.4, and 11.3 +/- 2.6 liters/h. The 24-h urinary recovery was independent of the dose and averaged 53% of the dose. After intramuscular administration of 1 g of cefotiam to three healthy volunteers, a mean (+/- standard deviation) peak concentration of 16.6 +/- 5.1 micrograms/ml was reached at 0.75 to 1 h post dosing. The concurrent intramuscular administration of lidocaine and cefotiam did not modify the kinetics of cefotiam. During a constant-rate infusion, the steady-state plasma clearance decreased slightly when the infusion rate was increased. There was no trend towards accumulation of cefotiam in plasma during chronic treatment with 1 g intravenously every 12 h for 10 days.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Daschner F. D., Hemmer K. A., Offermann P., Slanicka J. Pharmacokinetics of cefotiam in normal humans. Antimicrob Agents Chemother. 1982 Dec;22(6):958–960. doi: 10.1128/aac.22.6.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lecaillon J. B., Rouan M. C., Souppart C., Febvre N., Juge F. Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. J Chromatogr. 1982 Mar 12;228:257–267. doi: 10.1016/s0378-4347(00)80438-7. [DOI] [PubMed] [Google Scholar]
- Rouan M. C., Binswanger U., Bammatter F., Theobald W., Schoeller J. P., Guibert J. Pharmacokinetics and dosage adjustment of cefotiam in renal impaired patients. J Antimicrob Chemother. 1984 Jun;13(6):611–618. doi: 10.1093/jac/13.6.611. [DOI] [PubMed] [Google Scholar]
- Tsuchiya K., Kida M., Kondo M., Ono H., Takeuchi M., Nishi T. SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities. Antimicrob Agents Chemother. 1978 Oct;14(4):557–568. doi: 10.1128/aac.14.4.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wise R., Andrews J. M., Bedford K. A. Cefoperazone and cefotiam--two new cephalosporins: an in-vitro comparison. J Antimicrob Chemother. 1981 Apr;7(4):343–352. doi: 10.1093/jac/7.4.343. [DOI] [PubMed] [Google Scholar]